ISACA Research: Only Half of Organizations Say Their Leaders Are Digitally Literate
Only half (53 percent) of surveyed business technology professionals believe their organization’s leadership is digitally literate, according to ISACA’s new Digital Transformation Barometer research. The other 47 percent either don’t think their business leaders have a solid understanding of technology and its impacts, or are unsure. In addition, the global research study tempers the hype surrounding some emerging technologies, as respondents reality checked which technologies will be rapidly adopted, cautiously tested or parked for future consideration in the digital transformation crusade.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171114006801/en/
ISACA's Digital Transformation Barometer looks at the impact of digitally literate leaders and the hype vs. reality of emerging technologies. (Graphic: Business Wire)
The findings were released today and paint a concerning portrait for the progress to date, and future of digital transformation across the globe. The Digital Transformation Barometer data delves into digital transformation and digital literacy within leadership, as well as emerging and disruptive technologies within several industries. The full research report and additional resources can be found here.
“With this research, ISACA’s global membership provides a digital transformation reality check that assesses actual technology adoption plans, levels of sentiment of support and concern, and monetary commitments to deploy emerging technology by geography and industry,” said ISACA CEO Matt Loeb, CGEIT, CAE. “The resounding message from our research is clear: senior leadership needs to invest in increasing its digital fluency. Organizations with digitally fluent leadership are more clearly recognizing the benefits and risks of emerging technologies.”
Digital Literacy and Receptiveness to Emerging Technologies Among Leadership
A concerning 47 percent aren’t confident that their leaders are digitally literate, the data indicates. With nearly a quarter of these same leaders noted as needing a stronger understanding of technology’s benefits and risks, digital literacy of global organizations’ leadership across the industry and geographical spectrum is in question.
Despite the sense of urgency to embrace digital transformation across the board, less than a quarter of organizations said they believe their senior leadership is very receptive to adopting emerging technologies. Half of leadership teams are considered moderately receptive and one in five (20 percent) are not receptive.
Furthermore, challenges with digital literacy and receptivity to adopting emerging technology are not limited to the C-suite. Broader organizational challenges and cultural resistance play a role in the process of deploying certain digital transformation technologies.
- Almost half of global respondents anticipate facing organizational challenges or resistance when deploying AI/machine learning/cognitive tech (49 percent), public cloud (48 percent), and Internet of Things (46 percent).
- Roughly a third of respondents anticipate the same kind of resistance when deploying blockchain (34 percent) or big data analytics (31 percent).
Perceptions and Plans for Emerging Technologies: Hype vs. Reality
Big data analytics ranked highest in the chance of delivering transformational value to organizations (38 percent), easily besting AI/machine learning/cognitive (20 percent), public cloud (18 percent), IoT (14 percent), blockchain (7 percent), and AR/VR (2 percent). Big data analytics was also the leader in intended deployment plans for the coming year.
At this point, respondents believe AR/VR appears as more of a wishlist item rather than reality as most organizations are not deploying the technology yet.
The IoT and Public Cloud Are Still Considered Risky Business
Technologies such as Internet of Things lie at the heart of many companies’ digital transformation, but, according to the ISACA research, many respondents still consider IoT and public cloud to be quite risky:
- Sixty-six percent of global respondents ranked Internet of Things to be among the technologies as ‘high risk.’
- Perhaps because of the few, but very public, data breaches in the news that came from IoT devices, the resistance to IoT adoption is high in sectors most affected, including healthcare (71 percent) and government/military (69 percent).
- Seventy-four percent of surveyed business technology leaders are moderately to extremely concerned about their organization’s ability to safeguard connected devices in IoT.
“Emerging technologies have to be embraced,” said Loeb. “As the research shows, the reluctance to deploy them is linked to the need to understand and mitigate the risks of doing so. Organizations that implement a strong information and technology governance program will better understand their capabilities, which leads to more effective risk management and increased confidence in deployment of these technologies.”
About ISACA’s Digital Transformation Barometer
The ISACA Digital Transformation Barometer research, conducted in the second quarter of 2017, surveyed 4,164 information technology professionals worldwide. Results are at www.isaca.org/digital-transformation-barometer.
Nearing its 50th year, ISACA® (isaca.org) is a global association helping individuals and enterprises achieve the positive potential of technology.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27 | Tiedote
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi
Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 10:00 | Tiedote
SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme